Details for New Drug Application (NDA): 022024
✉ Email this page to a colleague
The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for 022024
Tradename: | ACTOPLUS MET XR |
Applicant: | Takeda Pharms Usa |
Ingredient: | metformin hydrochloride; pioglitazone hydrochloride |
Patents: | 2 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 15MG BASE | ||||
Approval Date: | May 12, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jul 31, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Jul 31, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM;EQ 30MG BASE | ||||
Approval Date: | May 12, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jul 31, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022024
Complete Access Available with Subscription